ImmuCell (NASDAQ:ICCC) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?

ImmuCell Corporation (NASDAQ:ICCC)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.18 and traded as low as $6.02. ImmuCell shares last traded at $6.14, with a volume of 3,341 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of ImmuCell in a research report on Monday, December 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell currently has a consensus rating of “Sell”.

ImmuCell Trading Up 0.8%

The company has a market capitalization of $55.11 million, a price-to-earnings ratio of 23.42 and a beta of 0.20. The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27. The company’s 50 day simple moving average is $5.77 and its two-hundred day simple moving average is $6.18.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $5.51 million for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

Institutional Investors Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC lifted its holdings in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 71,852 shares of the biotechnology company’s stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.